DOCSLIB.ORG

Materials Submitted to NIH from Reproductive Genetics Institute (RGI) Submissions #2009-ACD-006 & 2009-ACD-007

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Materials Submitted to NIH from Reproductive Genetics Institute (RGI) Submissions #2009-ACD-006 & 2009-ACD-007 Materials Submitted to NIH From Reproductive Genetics Institute (RGI) Submissions #2009-ACD-006 & 2009-ACD-007 (Both submissions have the same supporting documentation) I. Submission Cover Page (2009-ACD-006) p.l II. Submission Cover Page (2009-ACD-007) p. 11 III. Letter from RGI President p. 19 IV. Description of Supporting Information p. 20 V. Investigational Review Board Approval p. 25 VI. Research Consent p. 26 VII. Assurance Documents p. 31 VIII. Publications p. 38 IX. IIB Assurance p. 56 X. Additional Information: • Other Details via Email Correspondence p. 58 • IVF Clinical Consent (Couple A) p. 60 • Cryopreservation Consent (Couple A) p. 64 • Research Consent with Dates for Couple A; p. 69 (Document text is identical to Item VI, p. 26) • IVF Clinical Consent (Couple B) p. 74 • Research Consent with Dates for Couple B; p. 78 (Document text is identical to Item VI, p. 26) • Other Details via Email Correspondence p. 83 • Other Details via Email Correspondence p. 86 NOTE: Duplicative information in the submission is not included. Table of Clinical IVF and Research Consent Dates not included to protect patient privacy. List Page -hESC Registry Application Database Page 1 of 10 hESC Registry Application Database Detailed Listing for Request #: 2009-ACD-006 April 21, 2010 hESC Registry Application Search Results Request #: 2009-ACD-006 Organization: Reproductive Genetics Institute Status: Pending Org Address: 2825 North Halsted St., Chicago, IL 60657 USA DUNS: 790373369 Grant Number(s): n/a Review: ACD Signing Official (SO): Verlinsky Oleg / 773-472-4900 / [email protected] Submitter of Request: Strelchenko Nick / 773-472-4900 / Assurance: Yes (Section [email protected]:[email protected] Certification: Yes Submitter Comments: (None) Authority: Line #1: RG-148; DYSTROPHIA MYOTONICA 1 (DM1), affected, 46,XY Cell Lines: 24 NIH Approval #: Available: 24 Available: Yes Embryo from U.S.: Yes Previous #: Embryo Donated in Year(s): 2003 2009-DRAFT-022 Provider Name: Reproductive Genetics Institute Provider Phone: 773-472-4900 Email Provider Email: [email protected] Edit Provider URL: http://www.reproductivegenetics.com/ Delete Provider Restrictions: cell line limited for research purposes by Material Switch to ADM Transfer Agreement and cannot be used for experiment nuclear transfer and chimera production NIH Restrictions: Additional Information: Line #2: RG-153; DYSTROPHIA MYOTONICA 1 (DM1), affected, 46,XX NIH Approval #: Available: Yes Embryo from U.S.: Yes Embryo Donated in Year(s): 2003 Provider Name: Reproductive Genetics Institute Provider Phone: 773-472-4900 Provider. Email: [email protected] Provider URL: http://www.reproductivegenetics.com/ Provider Restrictions: cell line limited for research purposes by Material Transfer Agreement and cannot be used for experiment nuclear transfer and chimera production NIH Restrictions: i Additional Information: Line #3: RG-170; MUSCULAR DYSTROPHY, BECKER TYPE (BMD), affected, 46,XY NIH Approval #: Available: Yes Embryo from U.S.: Yes Embryo Donated in Year(s): 2004 http://hescregapp.od.nih.gov/login/list.htni?DetailList=yes&id=22 4/21/2010 List Page-hESC Registry Application Database Page 2 of 10 Provider Name: Reproductive Genetics Institute Provider Phone: 773-472-4900 Provider Email: [email protected] Provider URL: http://www.reproductivegenetics.com/ Provider Restrictions: cell line limited for research purposes by Material Transfer Agreement and cannot be used for experiment nuclear transfer and chimera production NIH Restrictions: Additional Information: Line #4: RG-186; HUNTINGTON DISEASE (HD), affected, 46,XX NIH Approval #: Available: Yes Embryo from U.S.: Yes Embryo Donated in Year(s): 2004 Provider Name: Reproductive Genetics Institute Provider Phone: 773-472-4900 ext.2158 Provider Email: [email protected] Provider URL: http://www.reproductivegenetics.com/ Provider Restrictions: cell line limited for research purposes by Material Transfer Agreement and cannot be used for experiment nuclear transfer and chimera production NIH Restrictions: Additional Information: Line #5: RG-194; HUNTINGTON DISEASE (HD), affected, 46,XY NIH Approval #: Available: Yes Embryo from U.S.: Yes Embryo Donated in Year(s): 2004 Provider Name: Reproductive Genetics Institute Provider Phone: 773-472-4900 ext.2158 Provider Email: [email protected] Provider URL: http://www.reproductivegenetics.com/ Provider Restrictions: cell line limited for research purposes by Material Transfer Agreement and cannot be used for experiment nuclear transfer and chimera production NIH Restrictions: Additional Information: Line #6: RG-233; HEMOGLOBIN BETA LOCUS (HBB), affected (HbS/HbS - sickle cell anemia), 46,XX NIH Approval #: Available: Yes Embryo from U.S.: Yes Embryo Donated in Year(s): 2005 Provider Name: Reproductive Genetics Institute Provider Phone: 773-472-4900 ext.2158 http://hescregapp.od.nih.gov/login/list.htm? 4/21/2010 List Page - hESC Registry Application Database Page 3 of 10 3 Provider Email: [email protected] Provider URL: http://www.reproductiveqenetics.com/ Provider Restrictions: cell line limited for research purposes by Material Transfer Agreement and cannot be used for experiment nuclear transfer and chimera production NIH Restrictions: Additional Information: Line #7: RG-245; EMERY-DREIFUSS MUSCULAR DYSTROPHY, X- LINKED (EDMD), carrier, 47,XXY NIH Approval #: Available: Yes Embryo from U.S.: Yes Embryo Donated in Year(s): 2005 Provider Name: Reproductive Genetics Institute Provider Phone: 773-472-4900 ext.2158 Provider-Email: [email protected] Provider URL: http://www.reproductivegenetics.com/ Provider Restrictions: cell line limited for research purposes by Material Transfer Agreement and cannot be used for experiment nuclear transfer and chimera production NIH Restrictions: Additional Information: Line #8: RG-246; EMERY-DREIFUSS MUSCULAR DYSTROPHY, X- LINKED (EDMD), affected, 46,XY NIH Approval #: Available: Yes Embryo from U.S.: Yes Embryo Donated in Year(s): 2005 Provider Name: Reproductive Genetics Institute Provider Phone: 773-472-4900 ext.2158 Provider Email: [email protected] Provider URL: http://www.reproductivegenetics.com/ Provider Restrictions: cell line limited for research purposes by Material Transfer Agreement and cannot be used for experiment nuclear transfer and chimera production NIH Restrictions: Additional Information: Line #9: RG-271; TORSION DYSTONIA 1 ( DYT1), AUTOSOMAL DOMINANT, affected (N/GAG del), 46,XY NIH Approval #: Available: Yes Embryo from U.S.: Yes Embryo Donated in Year(s): 2006 Provider Name: Reproductive Genetics Institute Provider Phone: 773-472-4900 ext.2158 http://hescregapp.od.nih.gov/login/list.htm?DetailList==yes&id=22 4/21/2010 List Page - hESC Registry Application Database Page 4 of 10 4 Provider Email: [email protected] Provider URL: http://www:reproductivegenetics.com/ Provider Restrictions: cell line limited for research purposes by Material Transfer-Agreement and cannot be used for experiment nuclear transfer and chimera production NIH Restrictions: Additional Information: Line #10: RG-283; MUSCULAR DYSTROPHY, DUCHENNE TYPE (DMD); affected, 46,XY NIH Approval #: Available: Yes Embryo from U.S.: Yes Embryo Donated in Year(s): 2006 Provider Name: Reproductive Genetics Institute Provider Phone: 773-472-4900 ext.2158 Provider Email: [email protected] Provider URL: http://www.reproductiveqenetics.com/ Provider Restrictions: cell line limited for research purposes by Material Transfer Agreement and cannot be used for experiment nuclear transfer and chimera production NIH Restrictions: Additional Information: Line#11: RG-288; CYSTIC FIBROSIS (CF), affected (deltaF508/deltaF508), 46,XY NIH Approval #: Available: Yes Embryo from U.S.: Yes Embryo Donated in Year(s): 2006 Provider Name: Reproductive Genetics Institute Provider Phone: 773-472-4900 ext.2158 Provider Email: [email protected] Provider URL: http://www.reproductiveqenetics.com/ Provider Restrictions: cell line limited for research purposes by Material Transfer Agreement and cannot be used for experiment nuclear transfer and chimera production NIH Restrictions: Additional Information: Line #12: RG-289; CYSTIC FIBROSIS (CF), affected (deltaF508/de!taF508), 46,XX NIH Approval #: Available: Yes Embryo from U.S.: Yes Embryo Donated in Year(s): 2006 Provider Name: Reproductive Genetics Institute Provider Phone: 773-472-4900 ext.2158 http://hescregapp.od.nih.gov/login/list.htm?DetailList=ves&id=22 4/21/2010 List Page - hESC Registry Application Database Page 5 of 10 Provider Email: [email protected] Provider URL: http://www.reproductivegenetics.com/ Provider Restrictions: cell line limited for research purposes by Material Transfer Agreement and cannot be used for experiment nuclear transfer and chimera production NIH Restrictions: Additional Information: Line #13: RG-301; MUSCULAR DYSTROPHY, DUCHENNE TYPE (DMD) affected, 46,XY NIH Approval #: Available: Yes Embryo from U.S.: Yes Embryo Donated in Year(s): 2006 Provider Name: Reproductive Genetics Institute Provider Phone: 773-472-4900 ext.2158 Provider Email: [email protected] Provider URL: http://www.reproductiveqenetics.com/ Provider Restrictions: cell line limited for research purposes by Material Transfer Agreement and cannot be used for experiment nuclear transfer and chimera production NIH Restrictions: Additional Information: Line #14: RG-302; MUSCULAR DYSTROPHY, DUCHENNE TYPE (DMD), carrier, 46,XX NIH Approval #: Available: Yes Embryo from U.S.: Yes Embryo Donated in Year(s): 2006 Provider Name: Reproductive Genetics Institute Provider
Load more

Recommended publications
  • FA Family News 3/01
    FAMILY NEWSLETTER #29 A Semi-annual Newsletter on Fanconi Anemia for Families, Physicians, and Research Scientists Spring 2001 Researchers, treating physicians, and FA parents attended the FA Scientific Symposium in October. HIGHLIGHTS Fanconi Anemia Plan to Attend August Scientific Symposium Family Meeting! Discoveries Reported...................2 One hundred fifty-six researchers, Our 10th annual FA Family Meet- Gene Therapy Trial to Begin.......2 treating physicians, and fifteen FA par- ing is seven months away, but now is ents from fourteen countries met in the time to start planning. This year, Bone Marrow Transplant Conference Planned .................2 Amsterdam for the Twelfth Annual we will offer a limited number of schol- International FA Scientific Sympo- arships to help families defray travel Comparison Between sium, October 26-29, 2000. Coun- and lodging expenses (see article, p. 11). Complementation Group and Mutations, and Clinical tries represented were Tunisia, France, From August 10-14, 2001, FA fam- Outcomes...................................3 England, Canada, Spain, Italy, Ger- ilies, treating physicians, and research- many, Argentina, Israel, Japan, South ers will meet at the picturesque lake- Fludarabine-Based Regimen for Alternate Donor Hemato- Africa, Russia, The Netherlands and front setting of Aurora University’s poietic Cell Transplantation....4 the United States. Fifty-one scientists George Williams Lake Geneva cam- and treating physicians gave formal pus in Williams Bay, Wisconsin. We New Promising Vectors for presentations. Evaluations from atten- will learn from our experts, meet and Gene Therapy ............................4 dees confirmed, once again, that our share experiences with other FA fam- Preimplantation Genetic annual scientific meeting is an out- ilies, and relax.
    [Show full text]
  • International Journal of Pediatrics and Neonatal Health, 2 (1)
    Twenty-seven years of controversy: The perils of PGD Item Type Article Authors Cherkassky, Lisa Citation Cherkassky, L. (2018) 'Twenty-seven years of controversy: The perils of PGD', International Journal of Pediatrics and Neonatal Health, 2 (1). Publisher BioCore Journal International Journal of Pediatrics and Neonatal Health Download date 25/09/2021 21:30:55 Link to Item http://hdl.handle.net/10545/622151 Lisa Cherkassky (2017). Twenty-Seven Years of Controversy: The Perils of PGD. Int J Ped & Neo Heal. 1:6, International Journal of Pediatrics and Neonatal Health ISSN 2572-4355 Review Article Open Access Twenty-Seven Years of Controversy: The Perils of PGD Lisa Cherkassky Senior Lecturer in Law, Derby Law School , University of Derby, UK *Corresponding Author: Lisa Cherkassky, Senior Lecturer in Law, Derby Law School , University of Derby, UK, Tel: 01332 591806, E-Mail: [email protected] Citation: Lisa Cherkassky (2017). Twenty-Seven Years of Controversy: The Perils of PGD. Int J Ped & Neo Heal. 1:6, Copyright: © 2017 Lisa Cherkassky. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Received November 28, 2017 ; Accepted December 08, 2017 ; Published XXXX, 2017. Abstract It has been 27 years since the Human Fertilisation and Embryology Act 1990 was passed in the United Kingdom in response to advances in fertility treatment. Preimplantation genetic diagnosis - the screening of embryos for genetic diseases - has led to lengthy ethical de- bates on sex selection, eugenics, disabilities, saviour siblings, surplus embryos and most recently, adult-onset diseases (the BRCA cancer gene).
    [Show full text]
  • The Ukrainian Weekly 1991
    їкЬей by the Ukrainian National Association Inc., a fraternal non-profit association! rainian WeeklУ Vol. LIX Ш THE UKRAINIAN WEEKLY SUNDAY, APRIL 21,1991 50 cents No. 16 Scientist says Chornobyl Miners, workers protest in Kiev claimed 10,000 lives Republican strike leader is arrested JERSEY CITY, N.J. - Vladimir explosion and that, "Three months ago by Marta Koiomayets arrived from all coal-producing regions Chernousenko, the scientific director in one of the people who participated in Kiev Press Bureau in Ukraine - from Volyn to Luhanske charge of the 20-mile exclusion zone limiting the damage of the accident died — on April 15 and 16 to demand that surrounding the Chornobyl nuclear in Kiev." KIEV - Dmytro Poyizd, the legal their government guarantee them and consultant for the newly formed the citizens of their republic a better power plant, said that the Chornobyl He further stated that "Some of the disaster claimed between 7,000 and Republican Strike Committee, was future — a future that includes free­ people involved in limiting the damage arrested early in the morning on Thurs­ dom for Ukraine. 10,000 lives, far more than the Soviet to Chornobyl received (radiation) doses government's official figures, reported day, April 18, just hours after he Angered upon learning the fate of one above the maximum...in fact 145 people organized a miners' and workers' sit-in of their leaders, the miners began the April 14 edition of the British came down with acute radiation newspaper Independent on Sunday. along the Khreshchatyk boulevard, planning anew strategy on Thursday sickness." Other scientists contacted at reported Bohdan Ternopilsky, vice- morning.
    [Show full text]
  • Genetic Testing
    GENETIC TESTING The transcript of a Witness Seminar held by the Wellcome Trust Centre for the History of Medicine at UCL, London, on 13 July 2001 Edited by D A Christie and E M Tansey Volume 17 2003 CONTENTS Illustrations v Introduction Professor Peter Harper vii Acknowledgements ix Witness Seminars: Meetings and publications xi E M Tansey and D A Christie Transcript Edited by D A Christie and E M Tansey 1 References 73 Biographical notes 91 Glossary 105 Index 115 ILLUSTRATIONS Figure 1 Triploid cells in a human embryo, 1961. 20 Figure 2 The use of FISH with DNA probes from the X and Y chromosomes to sex human embryos. 62 v vi INTRODUCTION Genetic testing is now such a widespread and important part of medicine that it is hard to realize that it has almost all emerged during the past 30 years, with most of the key workers responsible for the discoveries and development of the field still living and active. This alone makes it a suitable subject for a Witness Seminar but there are others that increase its value, notably the fact that a high proportion of the critical advances took place in the UK; not just the basic scientific research, but also the initial applications in clinical practice, particularly those involving inherited disorders. To see these topics discussed by the people who were actually involved in their creation makes fascinating reading; for myself it is tinged with regret at having been unable to attend and contribute to the seminar, but with some compensation from being able to look at the contributions more objectively than can a participant.
    [Show full text]
  • Over a Decade of Experience with Preimplantation Genetic Diagnosis a Multicenter Report
    FERTILITY AND STERILITY௡ VOL. 82, NO. 2, AUGUST 2004 CONTROVERSY: PREIMPLANTATION Copyright ©2004 American Society for Reproductive Medicine Published by Elsevier Inc. GENETIC DIAGNOSIS Printed on acid-free paper in U.S.A. Over a decade of experience with preimplantation genetic diagnosis: a multicenter report Yury Verlinsky, Ph.D.,a Jacques Cohen, Ph.D.,b Santiago Munne, Ph.D.,b Luca Gianaroli, M.D.,c Joe Leigh Simpson, M.D.,d Anna Pia Ferraretti, M.D.,c and Anver Kuliev, M.D., Ph.D.a Reproductive Genetics Institute, Chicago, Illinois; Saint Barnabas Medical Center, West Orange, New Jersey; and Societa Italiana Stukli di MEdicina della Reproduzione (SISMER), Bologna, Italy Objective: To review a 12-year experience of the world’s three largest preimplantation genetic diagnosis (PGD) centers. Design: Multicenter analysis of the clinical outcome of PGD. Setting: In vitro fertilization programs at the Reproductive Genetics Institute, Chicago, Illinois; Saint Barnabas Medical Center, West Orange, New Jersey; and SISMER, Bologna, Italy. Patient(s): Poor-prognosis IVF patients, patients carrying balanced chromosomal translocations, and couples at risk for producing children with Mendelian disorders. Intervention(s): In vitro fertilization, intracytoplasmic sperm injection, polar body removal, blastomere biopsy, and ET. Main Outcome Measure(s): DNA or chromosomal analysis of biopsied polar bodies or blastomeres, implantation and clinical pregnancy rates, and live-born pregnancy outcome. Result(s): A total of 754 babies have been born as a result of 4,748 PGD attempts, which shows the expanded application and the practical relevance of PGD for single-gene disorders, chromosomal aneuploidies and translocations, late-onset diseases with genetic predisposition, and nondisease testing in couples at need for human leukocyte antigens-matched offspring for treatment of affected siblings.
    [Show full text]
  • Preimplantation Diagnosis: a Realistic Option for Assisted Reproduction and Genetic Practice Anver Kuliev and Yury Verlinsky
    Preimplantation diagnosis: a realistic option for assisted reproduction and genetic practice Anver Kuliev and Yury Verlinsky Purpose of review Introduction Preimplantation genetic diagnosis (PGD) allows genetically Introduced 14 years ago, preimplantation genetic diag- disadvantaged couples to reproduce, while avoiding the nosis (PGD) permits genetic testing before the transfer of birth of children with targeted genetic disorders. By embryos to the mother, which has distinct advantages in ensuring unaffected pregnancies, PGD circumvents the establishing pregnancies unaffected by tested disorders possible need and therefore risks of pregnancy termination. and without the potential need for pregnancy termina- This review will describe the current progress of PGD for tion. Approximately 7000 PGD cases have been per- Mendelian and chromosomal disorders and its impact on formed worldwide, which have resulted in the birth of reproductive medicine. more than 1000 healthy children [1]. PGD can be used Recent findings for the diagnosis of late-onset diseases with genetic Indications for PGD have expanded beyond those used in predisposition, preimplantation HLA typing, and other prenatal diagnosis, which has also resulted in improved non-traditional prenatal testing; thus, PGD complements access to HLA-compatible stem-cell transplantation for other methods used in prenatal diagnosis [2]. By permit- siblings through preimplantation HLA typing. More than ting selection of euploid embryos for transfer, PGD 1000 apparently healthy, unaffected children have been improves reproductive outcome, which has resulted in born after PGD, suggesting its accuracy, reliability and its extensive use in assisted reproduction practices [1, safety. PGD is currently the only hope for carriers of 2–5]. This review will describe the current progress of balanced translocations.
    [Show full text]
  • Genetic Testing (V19) 3/11/03 8:46 Pm Page I
    Genetic Testing (v19) 3/11/03 8:46 pm Page i GENETIC TESTING The transcript of a Witness Seminar held by the Wellcome Trust Centre for the History of Medicine at UCL, London, on 13 July 2001 Edited by D A Christie and E M Tansey Volume 17 2003 ©The Trustee of the Wellcome Trust, London, 2003 First published by the Wellcome Trust Centre for the History of Medicine at UCL, 2003 The Wellcome Trust Centre for the History of Medicine at UCL is funded by the Wellcome Trust, which is a registered charity, no. 210183. ISBN 978 085484 094 6 All volumes are freely available online at: www.history.qmul.ac.uk/research/modbiomed/wellcome_witnesses/ Please cite as: Christie D A, Tansey E M. (eds) (2003) Genetic Testing. Wellcome Witnesses to Twentieth Century Medicine, vol. 17. London: Wellcome Trust Centre for the History of Medicine at UCL. Key Front cover photographs, top to bottom: Professor Marcus Pembrey Dr Patricia Tippett Professor Doris Zallen Professor Sir David Weatherall, Professor Charles Rodeck Inside front cover photographs, top to bottom: Professor John Woodrow Professor Rodney Harris Professor John Edwards (1928–2007) Professor Sue Povey Back cover photographs, top to bottom: Professor Ursula Mittwoch Professor Malcolm Ferguson-Smith Professor Matteo Adinolfi Professor Paul Polani (1914–2006) Inside back cover photographs, top to bottom: Professor Matteo Adinolfi, Professor Paul Polani (1914–2006) Professor Paul Polani (1914–2006), Professor Rodney Harris Professor Bernadette Modell Mrs Cathy Holding, Professor Alan Handyside Genetic Testing (v19) 3/11/03 8:46 pm Page iii CONTENTS Illustrations v Introduction Professor Peter Harper vii Acknowledgements ix Witness Seminars: Meetings and publications xi E M Tansey and D A Christie Transcript Edited by D A Christie and E M Tansey 1 References 73 Biographical notes 91 Glossary 105 Index 115 Genetic Testing (v19) 3/11/03 8:46 pm Page iv Genetic Testing (v19) 3/11/03 8:46 pm Page v ILLUSTRATIONS Figure 1 Triploid cells in a human embryo, 1961.
    [Show full text]
  • Preimplantation HLA Testing
    ORIGINAL CONTRIBUTION Preimplantation HLA Testing Yury Verlinsky, PhD Context Preimplantation genetic diagnosis (PGD) has become an option for couples Svetlana Rechitsky, PhD for whom termination of an affected pregnancy identified by traditional prenatal di- agnosis is unacceptable and is applicable to indications beyond those of prenatal di- Tatyana Sharapova, MS agnosis, such as HLA matching to affected siblings to provide stem cell transplanta- Randy Morris, MD tion. Mohammed Taranissi, MD Objective To describe preimplantation HLA typing, not involving identification of a causative gene, for couples who had children with bone marrow disorders at need for Anver Kuliev, MD, PhD HLA-matched stem cell transplantation. REIMPLANTATION GENETIC DIAG- Design, Setting, and Participants HLA matching procedures conducted at a single nosis (PGD) has become avail- site during 2002-2003 in an in vitro fertilization program for 9 couples with children able as an alternative to prena- affected by acute lymphoid leukemia, acute myeloid leukemia, or Diamond-Blackfan anemia requiring HLA-matched stem cell transplantation. In 13 clinical cycles, DNA in tal diagnosis in order to avoid single blastomeres removed from 8-cell embryos following in vitro fertilization was Pthe risk for pregnancy termination, be- analyzed for HLA genes simultaneously with analysis for short tandem repeats in the cause PGD allows selection of unaf- HLA region to select and transfer only those embryos that were HLA matched to fected embryos before a pregnancy is es- affected siblings. tablished. Despite the need for ovarian Main Outcome Measures Results of HLA matching and pregnancy outcome. stimulation and in vitro fertilization (IVF) to be part of the procedure, PGD Results As a result of testing a total of 199 embryos, 45 (23%) HLA-matched em- bryos were selected, of which 28 were transferred in 12 clinical cycles, resulting in 5 has become an acceptable method for singleton pregnancies and birth of 5 HLA-matched healthy children.
    [Show full text]
  • PREIMPLANTATION GENETIC DIAGNOSIS and PARENTAL PREFERENCES: BEYOND DEADLY DISEASE Susannah Baruch, J.D.*
    BARUCH 2-14.DOC 2/17/2009 5:28 PM 8 HOUS. J. HEALTH L. & POL’Y 245-270 245 Copyright © 2008 Susannah Baruch, Houston Journal of Health Law & Policy. ISSN 1534-7907 PREIMPLANTATION GENETIC DIAGNOSIS AND PARENTAL PREFERENCES: BEYOND DEADLY DISEASE Susannah Baruch, J.D.* I. Introduction .................................................................................................. 245 II. What is Preimplantation Genetic Diagnosis? .............................................. 247 III. Beyond Deadly Disease: Four Additional Ways Prospective Parents use PGD. .......................................................................................................... 251 A. HLA Matching to Save an Older Child ............................................ 253 B. Adult Onset Diseases........................................................................ 253 C. Non-Medical Sex Selection .............................................................. 253 D. Selection for a Disability.................................................................. 254 IV. PGD and Ethics.......................................................................................... 256 V. PGD Oversight............................................................................................ 261 VI. A Proposal for PGD Oversight in the United States. ................................. 267 VII. Conclusion................................................................................................ 270 I. INTRODUCTION Preimplantation genetic diagnosis (PGD) is the genetic
    [Show full text]
  • The Ukrainian Weekly 1991, No.16
    www.ukrweekly.com їкЬей by the Ukrainian National Association Inc., a fraternal non-profit association! rainian WeeklУ Vol. LIX Ш THE UKRAINIAN WEEKLY SUNDAY, APRIL 21,1991 50 cents No. 16 Scientist says Chornobyl Miners, workers protest in Kiev claimed 10,000 lives Republican strike leader is arrested JERSEY CITY, N.J. - Vladimir explosion and that, "Three months ago by Marta Koiomayets arrived from all coal-producing regions Chernousenko, the scientific director in one of the people who participated in Kiev Press Bureau in Ukraine - from Volyn to Luhanske charge of the 20-mile exclusion zone limiting the damage of the accident died — on April 15 and 16 to demand that surrounding the Chornobyl nuclear in Kiev." KIEV - Dmytro Poyizd, the legal their government guarantee them and consultant for the newly formed the citizens of their republic a better power plant, said that the Chornobyl He further stated that "Some of the disaster claimed between 7,000 and Republican Strike Committee, was future — a future that includes free­ people involved in limiting the damage arrested early in the morning on Thurs­ dom for Ukraine. 10,000 lives, far more than the Soviet to Chornobyl received (radiation) doses government's official figures, reported day, April 18, just hours after he Angered upon learning the fate of one above the maximum...in fact 145 people organized a miners' and workers' sit-in of their leaders, the miners began the April 14 edition of the British came down with acute radiation newspaper Independent on Sunday. along the Khreshchatyk boulevard, planning anew strategy on Thursday sickness." Other scientists contacted at reported Bohdan Ternopilsky, vice- morning.
    [Show full text]
  • Extracellular Matrix Stiffness and Geometry: the Impact on Static and Dynamic Cellular Systems in Vitro and the Treatment of Tissue Ischemia
    EXTRACELLULAR MATRIX STIFFNESS AND GEOMETRY: THE IMPACT ON STATIC AND DYNAMIC CELLULAR SYSTEMS IN VITRO AND THE TREATMENT OF TISSUE ISCHEMIA BY ARTEM A. SHKUMATOV DISSERTATION Submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy in VMS-Veterinary Pathobiology in the Graduate College of the University of Illinois at Urbana-Champaign, 2014 Urbana, Illinois Doctoral Committee: Assistant Professor Hyunjoon Kong, Chair Professor Marie-Claude Hofmann Professor Mark S. Kuhlenschmidt Professor Matthew Wallig Abstract Biologically relevant cell culture assays that can be adapted for high-throughput screening are very important for biopharmaceutical industry. Cellular material for such applications can represent static cultures that do not change over time, or dynamic (i.e. transformational) cultures based on pulripotent cells undergoing “cellular metamorphosis” and differentiating into a multitude of various descendant cell types – the process accompanied by formation of histologically complex tissues. Hydrogels being hydrophilic polymer-based adhesion matrices promote tissue-like microenvironments through tunable mechanical qualities and presentation of bioactive molecules. Moreover, hydrogel-based implants with controlled geometry can also be used for stem cell delivery and other therapeutic applications. This thesis investigates how main cell functions can be controlled by the matrix mechanical properties, with a goal to emulate physiological processes in vitro and potentiate stem cell treatments with appropriate bio-matrix design. First, I describe a method to promote advanced cardiomyogenic and endothelial differentiation within embryoid bodies through the control of three-dimensionality on collagen-polyacrylamide gels with tunable stiffness (Chapter 2). Next, the function of airway smooth muscle cells is investigated on substrates with physiological and pathological stiffnesses as it pertains to the cell adhesion, proliferation, calcium signaling and secretory function (Chapter 3).
    [Show full text]
  • Implications of Genetic Testing for Health Policy
    Yale Journal of Health Policy, Law, and Ethics Volume 10 Issue 1 Yale Journal of Health Policy, Law, and Article 2 Ethics 2010 Implications of Genetic Testing for Health Policy Gregory Katz Stuart O. Schweitzer Follow this and additional works at: https://digitalcommons.law.yale.edu/yjhple Part of the Health Law and Policy Commons, and the Legal Ethics and Professional Responsibility Commons Recommended Citation Gregory Katz & Stuart O. Schweitzer, Implications of Genetic Testing for Health Policy, 10 YALE J. HEALTH POL'Y L. & ETHICS (2010). Available at: https://digitalcommons.law.yale.edu/yjhple/vol10/iss1/2 This Article is brought to you for free and open access by Yale Law School Legal Scholarship Repository. It has been accepted for inclusion in Yale Journal of Health Policy, Law, and Ethics by an authorized editor of Yale Law School Legal Scholarship Repository. For more information, please contact [email protected]. Katz and Schweitzer: Implications of Genetic Testing for Health Policy Implications of Genetic Testing for Health Policy Gregory Katz* and Stuart 0. Schweitzert INTRODUCTION ............................................................................................... 92 I. THE DIFFUSION OF GENETIC TESTING AND ITS IMPACT ON MEDICAL PRACTICES ...................................................................................................... 93 A. MEDICAL PRACTICES AND NATIONAL DISPARITIES ................................ 94 B . ONLINE D ISTRIBUTION ...........................................................................
    [Show full text]